PUBLICATIONS

Our scientific achievements

A list of our publications detailing the results of our research, development and clinical trials of vaccines based on these results.

2024

Evaluation of Vaccine Immunogenicity—Correlates to Real-World Protection: Influenza

Csaba Laszlofy 1, Gyorgy Fazekas 2, Zoltan Barath 1, Zoltan Vajo 3 PMID: 38543806 PMCID: PMC10975834 DOI: 10.3390/v16030441

2019

Licensing the first reduced, 6 µg dose whole virion, aluminum adjuvanted seasonal influenza vaccine – A randomized-controlled multicenter trial

Zoltan Vajo 1, Laszlo Kalabay 2, Peter Vajo 3, Gergely Balaton 2, Noemi Rozsa 2, Peter Torzsa 2 PMID: 30497837 DOI: 10.1016/j.vaccine.2018.11.039

2017

Dose sparing and the lack of a dose-response relationship with an influenza vaccine in adult and elderly patients – a randomize, double-blind clinical trial

Zoltan Vajo 1, Gergely Balaton 1, Peter Vajo 2, Laszlo Kalabay 1, Adam Erdman 3, Peter Torzsa 1 PMID: 28378403 PMCID: PMC5555868 DOI: 10.1111/bcp.13289

2014

Influenza A(H5N1) pandemic prototype vaccine Fluval

Zoltan Vajo 1 PMID:19397418Pages 619-624 | Published online: 09 Jan 2014DOI:https://doi.org/10.1586/erv.09.25

2011

Lessons learnt from pandemic A(H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010)

Germaine Hanquet 1, Pierre Van Damme, Daniel Brasseur, Xavier De Cuyper, Simon Gregor, Martin Holmberg, Rebecca Martin, Zsuzsanna Molnár, Maria Grazia Pompa, René Snacken, Marianne van der Sande, Marc Van Ranst, Angela Wirtz, Pieter Neels PMID: 21075164 DOI: 10.1016/j.vaccine.2010.10.079

2010

A single-dose influenza A (H5N1) vaccine safe and immunogenic in adult and elderly patients: an approach to pandemic vaccine development

Zoltan Vajo 1, John Wood, Lajos Kosa, Istvan Szilvasy, Gyorgy Paragh, Zsuzsanna Pauliny, Kálmán Bartha, Ildiko Visontay, Agnes Kis, Istvan Jankovics PMID: 19906909 PMCID: PMC2812344 DOI: 10.1128/JVI.01894-09

2009

Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial

Prof Zoltan Vajo, MD Ferenc Tamas, MD Laszlo Sinka, MD Istvan Jankovics, MD Published:December 16, 2009DOI:https://doi.org/10.1016/S0140-6736(09)62039-0

Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains

György Fazekas 1, Rita Martosne-Mendi, Istvan Jankovics, Istvan Szilvasy, Zoltan Vajo PMID: 19020111 PMCID: PMC2668277 DOI: 10.1128/CVI.00327-08

Large trials confirm immunogenicity of H1N1 vaccines

Heath Kelly 1, Ian Barr PMID: 20018366 Published:December 16, 2009DOI:https://doi.org/10.1016/S0140-6736(09)62132-2

2008

Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children


Zoltan Vajo 1, Lajos Kosa, Istvan Szilvasy, Zsuzsanna Pauliny, Kálmán Bartha, Ildiko Visontay, Agnes Kis, Ildiko Tarjan, Noemi Rozsa, Istvan Jankovics
PMID: 18978514
DOI: 10.1097/INF.0b013e3181861dd7



Yearly licensing studies from 1997 to 2007 of the inactivated whole virus seasonal influenza vaccine fluval–a useful approach to pandemic vaccine development even in less well developed countries?

Zoltan Vajo 1, Lajos Kosa, Istvan Szilvasy, Zsuzsanna Pauliny, Kálmán Bartha, Ildiko Visontay, Mate Jankovics, Agnes Kis, Istvan Jankovics PMID: 19453398 PMCID: PMC4634116 DOI:10.1111/j.1750-2659.2008.00055.x

2007


Inactivated whole virus influenza A (H5N1) vaccine

Zoltan Vajo, Lajos Kosa, Ildiko Visontay, Mate Jankovics, Istvan Jankovics PMID: 18044056 PMCID: PMC2738456 DOI: 10.3201/eid1305.061248

Scroll to Top